

WHO Advisory Committee on Variola Virus Research

Report of the Fourteenth Meeting

Geneva, Switzerland
16–17 October 2012

WHO Advisory Committee on Variola Virus Research

Report of the Fourteenth Meeting

Geneva, Switzerland

16–17 October 2012



© World Health Organization 2013

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts [or give name of group] and does not necessarily represent the decisions or the policies of the World Health Organization.

Table of Contents

Executive summary	3
1. Opening	4
2. Report of the Secretariat	4
3. Update on research proposals submitted to WHO in 2011	5
4. Report on the variola collection at the WHO Collaborating Centre repository in SRC VB VECTOR, Koltsovo, Novosibirsk Region, Russian Federation	5
5. Report on the variola virus collection at the WHO Collaborating Center for Smallpox and other Poxviruses at the Centres for Disease Control and Prevention Atlanta, GA, USA	6
Variola virus research 2011–2012 update	7
6. Use of live variola virus to develop protein based diagnostic and detection assays specific for variola virus / Use of live variola virus to maintain and regenerate non-infectious variola derived materials for diagnostic development support	7
7. Discovery of new antivirals for smallpox treatment and prevention / Development of therapeutic anti-smallpox antibodies / Assessment of the neutralizing activity of vaccine blood sera using live variola virus	8
8. Use of live variola virus to determine whether CAST/EiJ mice are a suitable animal model for human smallpox	9
9. Use of live variola virus to evaluate antiviral agents against variola	9
10. Use of live variola virus in systems kinomics for identification of host targets for therapeutic intervention	10
11. Use of live variola virus to support less-reactogenic vaccine development	11
12. Efficacy study of the therapeutic window of oral ST-246® in cynomolgus monkeys infected with variola virus	12
13. New generation smallpox vaccines	13
14. FDA efforts to facilitate the development and approval of smallpox medical countermeasures .	13
15. Progress towards approval of ST-246®	15
16. Progress on the development of smallpox vaccine IMVAMUNE®	16
17. Update on LC16m8 vaccine	17
18. Update on hexadecyloxypropylcidofovir (CMX001) therapeutic development for smallpox	17
19. WHO smallpox vaccines: update	18
20. Update on variola virus repositories biosafety inspection visits in 2012	19
21. The Smallpox Laboratory Network	19
22. General discussion	20
23. Conclusions	22

WHO Advisory Committee on Variola Virus Research
Report of the Fourteenth Meeting, Geneva, Switzerland, 16–17 October 2012

Annex 1. Summaries of the presentations	24
Annex 2. Agenda	46
Annex 3. List of participants	49

Executive summary

Variola virus research performed under supervision of WHO was presented to the WHO Advisory Committee on Variola Virus Research. It may be summarized as follows.

The Committee noted that the work under the authorized programme of research with variola virus had been done under its supervision. In 2012, nine projects had been approved by its scientific subcommittee and progress reports were presented at the meeting.

The Committee received reports on the virus collection held at the two WHO Collaborating Centres authorized as repositories of variola virus: the State Research Center for Virology and Biotechnology (Russian Federation) and the Centers for Disease Control and Prevention (United States of America).

In addition, the Committee received updates from three pharmaceutical companies on advanced candidate vaccines and antivirals. Information presented included data on efficacy, safety, stability and large-scale manufacturing capacity. Work is continuing on the studies that are needed in order to satisfy the requirements for eventual regulatory approval.

The Committee heard that limited progress had been made in establishing a laboratory network for diagnosis of smallpox and other orthopoxvirus infections due to a variety of logistic issues. WHO informed the Committee that Headquarters and Regional Offices will identify and select facilities with appropriate capacities for this purpose from existing diagnostic laboratories for dangerous pathogens.

A variola-virus-specific diagnostic test based on existing tests and with the capacity to distinguish between variola and other poxviruses is being refined.

Both authorized repositories of variola virus were inspected during 2012 and the final reports of these biosafety inspections will be posted on the WHO web site. The protocol used followed the European Committee for Standardization's Laboratory Biorisk Management Standard CWA 15793:2011 and addressed 16 elements of laboratory biorisk management.

1. Opening

- 1.1. The 14th meeting of the WHO Advisory Committee on Variola Virus Research (ACVVR) took place in WHO Headquarters, Geneva, Switzerland, from 16 to 17 October 2012 with Professor G.L. Smith as Chairman and Dr R. Drillien as Rapporteur. Dr K. Fukuda, WHO Assistant Director-General for Health Security and Environment welcomed participants on behalf of WHO. Dr Fukuda reminded the Committee of the 2007 World Health Assembly (WHA) resolution 60.1, which noted that authorization was granted to permit essential research for global public health benefit including further research into antiviral agents and safer vaccines. He thanked the ACVVR for conducting yearly reviews of the research programmes involving live variola virus. He reminded the Committee that nine proposals for research on live virus had been submitted and reviewed by the ACVVR scientific subcommittee since the last meeting and that progress in each area would be presented at this meeting. He informed the Committee that inspections of the two WHO Collaborating Centres had been carried out in 2012. The reports of these inspections would shortly be made publicly available. He also reminded the Committee that an operational framework for distributing the current vaccine stockpiles administered by WHO including both physical stocks in Geneva and vaccines pledged to WHO was being set up according to standardized operating procedures.

2. Report of the Secretariat

- 2.1. Dr A. Costa presented the report of the WHO Secretariat. He recalled that biosafety inspections of the two WHO Collaborating Centres had been carried out in 2012 at the Centers for Disease Control and Prevention (CDC), United States of America, during 7–11 May and at VECTOR, Russian Federation, during 3–10 October. He summarized the strategic preparedness plan that was being revised by WHO since the beginning of 2012 to deal with any smallpox outbreak. The plan included the handling of vaccine stockpiles, the creation of a diagnostic laboratory network, the identification of appropriate assays and the sharing of information between experts. He indicated that the Smallpox Laboratory Network would be included within the WHO dangerous pathogens network to ensure efficient use of resources. Dr Costa informed the Committee that WHO has consulted with the countries which pledged vaccines in order to ensure emergency coordination of and access to the

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28162

